info@siftdesk.org

21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.

Affiliation

Department of Surgery, University of Minnesota, United States. Electronic address: [Email]

Abstract

The 21-gene recurrence score (RS) (Oncotype Dx, Genomic Health, Redwood City Ca) has not been validated in an older cohort with estrogen receptor (ER)-positive breast cancer. The objective of this study was to evaluate RS validity in a group of older women with ER-positive breast cancer.

Keywords

Breast Cancer,Genomic Testing,Geriatric,Recurrence Score,

OUR JOURNALS

Having over 250 Research scholars worldwide and more than 400 articles online with open access.

OUR Recent Articles